To conduct non-clinical good laboratory practice (GLP) in vivo genotoxicity and reproductive toxicology and GLP development and reproductive (DART) toxicology studies.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93023C00051
- Awardee
-
Arisan Therapeutics Inc. UEI PYRKTQPNVJZ8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,692,037
Award facts
- Opportunity
-
- HHSNIHNIAIDBAA202301 Solicitation number
- Contract value 100% obligated
- $3,692,037.00 Current and potential, with all options
- Completion date 95% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Carlsbad, CA 92008, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,692,037 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Arisan Therapeutics Inc. for non-clinical Good Laboratory Practice in vivo genotoxicity and reproductive toxicology and DART toxicology studies on September 22, 2023, with a ceiling value of $3.692 million under cost-plus-fixed-fee pricing.
Place of performance is Carlsbad, California. The contract runs through December 31, 2026.
Service Contract Inventory reporting shows actual government-invoiced labor across three fiscal years. FY2024 represented the contract's heaviest utilization: $2.5 million invoiced against 0.4 FTEs and 912 contractor hours, yielding a derived hourly rate of $2,745.93. FY2025 activity declined to 0.3 FTEs and $606 thousand invoiced. FY2023 carried minimal activity ($2 thousand, 15 hours). Arisan self-performed all reported hours; no subcontractors appear in the SCI record.
Quick answers
Who was awarded contract 75N93023C00051?
75N93023C00051 was awarded to Arisan Therapeutics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 22, 2023.
How much is contract 75N93023C00051 worth?
The government has obligated $3,692,037 on 75N93023C00051.
Was contract 75N93023C00051 competed?
The extent of competition for 75N93023C00051 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award